Source: Eur Respir J 2008; 32: 503-512
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Warwick G., Thomas P. S., Yates D. H.. Biomarkers in pulmonary hypertension. Eur Respir J 2008; 32: 503-512

Member's Comments

No comment yet.

Related content which might interest you: N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 509-513 Year: 2005 Association of haemodynamic parameters with circulating natriuretic peptides in precapillary pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pulmonary hypertension and renal insufficiency Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Asymmetric dimethylarginine, a biomarker for the effects of drug therapy in pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers Year: 2012 Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension Source: Eur Respir J 2010; 35: 95-104 Year: 2010 Can brain natriuretic peptide (BNP) be a predictor for pulmonary arterial hypertension? Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Pathophysiology of pulmonary arterial hypertension Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=191 Year: 2004 The diagnostic value of N-terminal pro-C-type natriuretic peptide in COPD patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012 The role of the biomarker and the genetic polymorphism of endothelin-1 in pulmonary arterial hypertension among Egyptians Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Eur Respir J 2008; 32: 1289-1294 Year: 2008 Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 The association between pulmonary arterial hypertension secondary to chronic lung disease and serum asymmetric dimethylarginine levels Source: Annual Congress 2012 - COPD comorbidities II Year: 2012 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Identification of left ventricular systolic dysfunction or pulmonary hypertension in patients with asthma or chronic obstructive pulmonary disease by N-terminal pro-brain natriuretic peptide Source: Annual Congress 2007 - New insight into the pathophysiology of asthma Year: 2007 Natriuretic peptides levels and heart remodeling in different forms of pulmonary hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways Source: Eur Respir J 2013; 41: 1116-1125 Year: 2013